$26.76
Today
as of Sep 4, 16:50 ET
Last 30 days
Recent Press Releases & News
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Wedbush Adjusts Price Target on Immunome to $35 From $31, Keeps Outperform Rating
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
Overview
52-week range
$8.66
$30
85% of range
Avg surprise (last 3)
+15.0%
Avg reaction (last 2)
+2.5%
50% positive
Latest IV / EM
47%
EM ±8.4% · $27 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.65 | — | — | — | — | financials |
| Tue May 12, 2026 | Mar/2026 | $-0.48 | $-0.60 | +20.0% | +7.7% | -1.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.65 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.50 | $-0.52 | +3.9% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.52 | $-0.66 | +21.2% | — | +6.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.78 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.60 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-2.51 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.36 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.46 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.35 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | $0 | $4M | $3M | — | $3M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-78M | $-59M | — | $-60M | $-46M | $-45M | — | $-51M |
| Net income | $-73M | $-54M | — | $-57M | $-43M | $-42M | — | $-47M |
| EPS (diluted) | $-0.65 | $-0.48 | — | $-0.65 | $-0.50 | $-0.52 | — | $-0.78 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $218M | $583M | $653M | $273M | $144M | $258M | $143M | $156M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $538M | $594M | $661M | $280M | $277M | $323M | $221M | $244M |
| Total assets | $565M | $620M | $683M | $299M | $296M | $343M | $240M | $257M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $40M | $31M | $49M | $35M | $27M | $36M | $59M | $42M |
| Total equity | $525M | $589M | $634M | $264M | $269M | $307M | $181M | $215M |